In vitro effects of the prenyl transferase inhibitor AZD3409 on prostate cancer epithelial cells.

R. Khafagy,T. Stephens,C. Hart,V. Ramani,M. Brown,N. Clarke

DOI: https://doi.org/10.1200/JCO.2004.22.14_SUPPL.4744

IF: 45.3

2004-07-15

Journal of Clinical Oncology

Abstract:4744 Background: Prostate cancer is the most common malignancy in men with a predilection to metastasize to the bone. There is a requirement for a chemotherapeutic agent capable of preventing or slowing down the growth of bone metastases. AZD3409 is a novel oral prenyl transferase inhibitor with anticancer potential. METHODS The effect of escalating doses of AZD3409 on proliferation of the malignant PC-3 and LNCaP, and non-malignant PNT2-C2 prostate epithelial cell lines was determined by CASY TT cell counter. PC-3 and PNT2-C2 colony formation was studied in co-culture using long-term human bone marrow stroma harvested from individuals with benign disease. Prostatic epithelial colony growth was measured using standardized quantitative techniques in the presence of escalating doses of AZD3409. Prostatic cellular invasion through matrigel (synthetic basement membrane) and cultured endothelial monolayers was measured in invasion chambers in the presence and absence of drug using cytokeratin labeled quantitation of migrating cells. RESULTS AZD3409 displayed marked anti-proliferative properties on non-malignant (PNT2-C2) and malignant (PC-3 and LNCaP) prostate epithelial cells, with a concentration of 10 nM resulting in a 50% inhibition of growth after 5 days. AZD3409 inhibits invasion through bone marrow endothelium towards bone marrow stroma, with a concentration of 4 μM inhibiting 50% of PC-3 invasion. Pre-treatment resulted in a 1000-fold decrease in the invasion IC50 with inhibition of invasion occurring at 10 nM, levels known to be attainable in vivo. AZD3409 inhibits colony formation in bone marrow stroma co-cultures resulting in reduced numbers of colonies (50% inhibition at 4 μM) and a reduction in epithelial colony size (50% reduction at 8 μM). CONCLUSIONS AZD3409 is a potent inhibitor of prostate epithelial cell proliferation and its anti-colony formation in bone marrow stroma co-culture suggests potential as an anti-metastatic agent. This hypothesis is strengthened by the fact that AZD3409 shows significant inhibition of prostate cancer cell invasion through human bone marrow endothelium. [Table: see text].